
CLAIMS

1. A pharmaceutical combination product ~~presented in the form of a dry powder composition for administration via a dry powder inhaler~~ comprising

a) a compound of formula (I):



(I)

wherein X^- is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate; and

b) fluticasone furoate present in an amount of 100mcg/dose;

and further wherein the product does not comprise any further therapeutically active agents.

2. A product according to claim 1, wherein the compound of formula (I) is umeclidinium bromide.

3. A product according to claim 1 or 2, wherein the compound of formula (I) and the corticosteroid are presented as separate compositions.

4. A product according to claim 3, wherein both compositions of the compound of formula (I) and the corticosteroid contain a carrier, wherein the carrier is lactose.

5. A product according to claim 3 or 4, wherein at least one of said compositions contains a ternary agent, wherein the ternary agent is magnesium stearate.

6. A product according to claim 5, wherein magnesium stearate is present in an amount of about 0.6%w/w in a composition of the compound of formula (I).

7. A product according to any of claims 1 to 6, wherein said separate compositions are in unit dose form, wherein the unit dose is in a capsule, cartridge or blister pack.

8. A product according to claim 7, wherein the free cation of the compound of formula (I) is present in an amount of 125mcg/dose, 62.5mcg/dose, 31.25mcg/dose or 15.625mcg/dose.

9. A dry powder inhaler containing a product according to claim 1, which comprises ~~comprising~~ two compositions presented separately in unit dose form, wherein the first composition comprises

i. umeclidinium bromide, and
ii. lactose, and
iii. magnesium stearate at an amount of about 0.6%w/w based on the total weight of the first composition;

and the second composition comprises

i. fluticasone furoate present in an amount of 100mcg/dose, and
ii. lactose.

10. A dry powder inhaler according to claim 9, wherein the unit dose form is a capsule, cartridge or blister.

11. A dry powder inhaler according to claim 9 or 10 wherein umeclidinium bromide is present in an amount of 125mcg/dose, 62.5mcg/dose, -31.25mcg/dose or 15.625mcg/dose of the free cation.

12. A product as defined in any of claims 1 to 11 for use in therapy.

13. A product as defined in any of claims 1 to 11 for use in the treatment of inflammatory or respiratory tract diseases.